Clinical Trial

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Study acronym: ATRIUM
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-04-15; most recent amendment 2025-10-25.
Status change: Not Yet Recruiting → Recruiting 2024-06-04
Trial Details
NCT Number NCT06376916
Lead Sponsor Wake Forest University Health Sciences
Conditions Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Enrollment 153 participants
Start Date 2024-10-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-28